NMS Group

NMS Group is a leading oncology-focused Italian contract research and drug development organization with a strong heritage in kinase inhibitor discovery and clinical development. Its integrated structure enables end-to-end R&D from target identification and validation, through preclinical and early clinical development, up to commercial manufacturing. The company has multiple programs at various clinical stages, with recent expansion into DNA damage response (DDR), antibody-drug conjugates (ADCs), and molecularly targeted therapies. NMS Group emphasizes personalized medicine, global collaborations, and a growing focus on cancers prevalent in Asia, especially Greater China.